Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital PIC

Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China

Fineline Cube Aug 26, 2026
Company Deals

Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset – Up to USD 1.46 Billion in Milestones

Fineline Cube Aug 26, 2026
Company Deals PIC

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Fineline Cube Aug 25, 2026
Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company Drug PIC

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

Fineline Cube Aug 26, 2026
Company Drug

Humanwell Healthcare Gains NMPA Approval for Giapreza Generic in Shock Therapy

Fineline Cube May 9, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clinical trial...

Company Drug

Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial

Fineline Cube May 9, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clearance from...

Company Deals

Pfizer Partners with HSITP to Boost Life Sciences Innovation in Greater Bay Area

Fineline Cube May 9, 2025

US giant Pfizer Inc. (NYSE: PFE) has entered into a partnership with Hong Kong-Shenzhen Innovation...

Company Deals

Insilico Medicine Files for IPO to Leverage AI in Drug Discovery

Fineline Cube May 9, 2025

China-based Insilico Medicine, a biotech company leveraging generative artificial intelligence (AI), has filed for an...

Company Drug

Pfizer’s Zavicefta Approved by China’s NMPA for Severe Infections in All Ages

Fineline Cube May 9, 2025

US-based pharmaceutical giant Pfizer (NYSE: PFE) announced that it has received market approval from China’s...

Company Drug

Amgen’s Tepezza Approved in UK for Thyroid Eye Disease Treatment

Fineline Cube May 9, 2025

US biotech Amgen (NASDAQ: AMGN) announced that the UK’s Medicines and Healthcare products Regulatory Agency...

Company Deals

Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing

Fineline Cube May 8, 2025

China-based Guangzhou Regenverse Therapeutics Co., Ltd (former name: Guangzhou Regen Therapeutics Co., Ltd.), a developer...

Company

Novo Nordisk Reports 18% YOY Revenue Growth in Q1 2025

Fineline Cube May 8, 2025

Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) released its Q1 2025 earnings report this week....

Company Deals Drug

Sino Biopharmaceutical and JD Healthcare Forge Comprehensive Strategic Partnership

Fineline Cube May 8, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) and JD Healthcare, a unit of China’s e-commerce giant...

Company Deals

Adicon Holdings Acquires Suzhou Youqin Medical Laboratory and Yuande Weikang

Fineline Cube May 8, 2025

China-based independent clinic laboratory (ICL) service provider Adicon Holdings Ltd (HKG: 9860) announced the acquisition...

Company Deals

Oricell Partners with Umoja Biopharma to Develop In Vivo CAR-T Cell Therapies

Fineline Cube May 8, 2025

China-based Oricell Therapeutics Co., Ltd. announced a strategic partnership agreement with US-headquartered Umoja Biopharma Inc....

Company

BeiGene’s Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales

Fineline Cube May 8, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...

Company Drug

European Commission Approves J&J’s Tremfya for Crohn’s Disease Treatment

Fineline Cube May 8, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved Tremfya...

Company

Amgen Reports 9% Revenue Growth in Q1 2025, Driven by Double-Digit Product Sales

Fineline Cube May 8, 2025

US biotech Amgen (NASDAQ: AMGN) revealed its 2025 Q1 financial results, recording USD 8.1 billion...

Company Drug

AstraZeneca and Daiichi Sankyo Announce Positive DESTINY-Breast11 Trial Results for Enhertu

Fineline Cube May 8, 2025

Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced the positive preliminary results from...

Company

Siemens Healthineers Reports Q2 2025 Revenue Up 6.8% to EUR 5.909 Billion

Fineline Cube May 8, 2025

Germany-based Siemens Healthineers AG (ETR: SHL) released its financial report for the second quarter of...

Company Drug

Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer

Fineline Cube May 8, 2025

China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that a filing to conduct a Phase...

Company

Biogen Reports 8% YOY Sales Growth in Q1 2025, Driven by Rare Disease Therapies

Fineline Cube May 7, 2025

According to Biogen Inc.’s (NASDAQ: BIIB) Q1 2025 report released this week, the US firm...

Company Drug

Zhongsheng Pharma’s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction

Fineline Cube May 7, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose...

Company Deals

Alchemab Therapeutics Licenses ATLX-1282 to Eli Lilly for ALS Treatment

Fineline Cube May 7, 2025

UK-based biotech Alchemab Therapeutics Ltd entered into a licensing agreement with US major Eli Lilly...

Posts pagination

1 … 212 213 214 … 712

Recent updates

  • NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer
  • FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab
  • FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma
  • MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan
  • WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Company Drug PIC

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

Company Drug PIC

FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma

Company Drug PIC

MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.